Aiforia releases another CE-IVD marked clinical AI Model — expanding its diagnostic pathology offering to prostate cancer
Aiforia Technologies Plc, Press Release, 27 May, 2022 at 09.30 a.m. EEST. Aiforia Technologies Plc announces the CE-IVD marking of the Aiforia® Clinical AI Model for Prostate Cancer; Gleason Grade Groups. This latest regulatory certification brings Aiforia’s portfolio of AI-powered diagnostic tools to a total of 5 CE-IVD marked clinical AI models for breast, lung, and now prostate cancer — the most commonly occurring cancer in men.
According to the World Cancer Research Fund, more than 1.4 million new cases of prostate cancer were diagnosed in 2020. Both pathologists and patients deserve reliable and efficient tools for prognostics, diagnostics, and guiding treatment pathways. Gleason grading is the strongest predictor of outcome for the disease.
The latest CE-IVD marked AI model brings automation and consistency to prostate cancer diagnostics. The deep learning-based tool is able to automatically detect and grade tumor areas in prostate tissue images from whole slide images (WSI) to assess Gleason patterns — the most common system for grading prostate cancer. Gleason Grades are assigned to prostate tissue samples to represent how cancerous the tissue is.
“AI solutions will develop to aid prostate cancer diagnostics further, beyond the augmented Gleason grade assessment. Ideally, AI will help in the development of novel ways in patient stratification and treatment decision making, also when histology-based models are combined with other types of data,” explains Dr. Tuomas Mirtti, Consulting Clinical Pathologist and Chief Physician in the Helsinki University Hospital Diagnostic Center in Finland.
“Only a few days ago we announced the release of our CE-IVD marked Aiforia® Clinical AI Model for Breast Cancer; PR. Aiforia is now only one AI model away from reaching its business target; obtaining the CE-IVD marking for 6 AI models intended for clinical diagnostics. We have achieved this versatile portfolio of robust tools for pathologists and pathology labs in the diagnostic support of some of the world’s most common cancers, in just a few short months. I believe this is a testament to the highly skilled team we have at Aiforia,” explains Jukka Tapaninen, CEO of Aiforia Technologies.
Further enquiries
Emma Vehviläinen, CMO, Aiforia Technologies Plc, tel. +358406675204
Jukka Tapaninen, CEO, Aiforia Technologies Plc, tel. +33610416686
https://investors.aiforia.com/
Certified Adviser
UB Securities Ltd, tel. +358 9 25 380 225
About Aiforia
Aiforia equips pathologists and scientists in preclinical and clinical labs with powerful deep learning artificial intelligence software for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia products and services aim to escalate the efficiency and precision of medical image analysis beyond current capabilities, across a variety of fields from oncology to neuroscience and more. Find out more: www.aiforia.com
